Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice.
OBJECTIVE
To study the anti-HIV-1 effects of the delivery of anti-gp41 monoclonal antibody (mAb) and soluble CD4 (sCD4) immunoadhesin by genetically modified cells in HIV-1-infected, humanized severe combined immunodeficient (SCID) mice.


METHODS
The complementary DNA of mAb 2F5, an anti-HIV-1 gp41 antibody, and of sCD4-IgG chimeric immunoadhesin were transferred into 3T3 cells using Moloney murine leukaemia virus vectors. The cells were then incorporated into a collagen structure called the neo-organ, which allowed the continuous production of the therapeutic molecules.


METHODS
The antiviral effects in vivo of 2F5 or sCD4-IgG or both compounds were evaluated in neo-organ-implanted SCID mice that were grafted with human CD4 CEM T cells and challenged with HIV-1 Lai or MN.


RESULTS
In SCID mice implanted with 2F5 neo-organs, antibody plasma levels reached 500-2000 ng/ml. Viral loads after HIV-1 challenge were significantly reduced in neo-organ-implanted HIV-infected mice. Although 29 x 10(7) and 13 x 10(8) HIV-1-RNA copies/ml were detected at 12 days in the controls (mice injected with Lai and MN, respectively) less than 16.5 x 10(3) HIV-1-RNA copies/ml were observed in all implanted mice injected with either Lai or MN. The intracellular viral load was also reduced in CD4 cells recovered from the implanted mice. Comparable antiviral effects were obtained with CD4-IgG neo-organs.


CONCLUSIONS
Our results confirm the anti-HIV properties of 2F5 and sCD4-IgG continuously produced in vivo after ex-vivo gene therapy in SCID mice.
Sanhadji
K
K
Laboratoires des Déficits Immunitaires et de Rétrovirologie, Faculté de Médecine RTH Laënnec, Lyon, France.
Grave
L
L
Touraine
J L
JL
Leissner
P
P
Rouzioux
C
C
Firouzi
R
R
Kehrli
L
L
Tardy
J C
JC
Mehtali
M
M
D016475:3T3 Cells / Q000637:transplantation; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D016860:CD4 Immunoadhesins / Q000235:genetics / Q000627:therapeutic use*; D004279:DNA, Viral / Q000032:analysis; D004195:Disease Models, Animal; D015316:Genetic Therapy; D015483:HIV Antibodies / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D015700:HIV Envelope Protein gp41 / Q000276:immunology*; D015658:HIV Infections / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000472:pathogenicity / Q000502:physiology; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D014161:Transduction, Genetic; D019562:Viral Load
D000911:Antibodies, Monoclonal; D016860:CD4 Immunoadhesins; D004279:DNA, Viral; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41